혈전 제거 기기 시장 : 디바이스 유형별, 시술 유형별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Blood Clot Retrieval Devices Market is projected to grow by USD 6.06 billion at a CAGR of 14.80% by 2032.

Blood clot retrieval devices, including stent retrievers, aspiration catheters, balloon guide catheters, and adjunctive access systems, are central to endovascular thrombectomy for acute ischemic stroke caused by large vessel occlusion. The clinical foundation is strong: randomized trials published in 2015 and subsequent guideline updates from the American Heart Association/American Stroke Association and European Stroke Organisation established mechanical thrombectomy as standard care for eligible patients, with selection commonly extending from 0-6 hours and up to 24 hours in carefully imaged patients.

Demand is supported by the global stroke burden. The World Health Organization identifies stroke as one of the leading causes of death and disability worldwide, while Global Burden of Disease research reports more than 12 million new strokes annually. For hospitals, payers, and device manufacturers, the market is increasingly defined by faster reperfusion, improved first-pass effect, broader access to comprehensive stroke centers, and evidence-based integration of neurointerventional workflows.

Transformative Shifts in the Blood Clot Retrieval Landscape

The blood clot retrieval devices landscape is shifting from device-only competition toward system-level stroke care. Clinical adoption is being shaped by advanced imaging, mobile stroke units, telestroke networks, direct-to-angiosuite protocols, and transfer models that reduce door-to-groin and door-to-reperfusion times. The most competitive device strategies now address procedural efficiency, navigability, clot integration, aspiration force, and compatibility across complex neurovascular anatomy.

Regulatory and purchasing dynamics are also transforming the market. The U.S. FDA continues to emphasize safety and performance evidence for neurovascular devices, while the European Union Medical Device Regulation has raised documentation and clinical evaluation requirements. At the same time, health systems are prioritizing outcomes, length-of-stay reduction, and stroke network coverage, making real-world evidence, physician training, and post-market surveillance essential differentiators.

Cumulative Impact of Artificial Intelligence on Thrombectomy Care

Artificial intelligence is becoming a practical growth catalyst for blood clot retrieval devices by improving the speed and consistency of stroke identification. AI-enabled imaging platforms are used to flag suspected large vessel occlusion on CT angiography, estimate infarct core and penumbra on perfusion imaging, support ASPECTS scoring, and notify stroke teams. These tools align with guideline-based thrombectomy pathways because clinical benefit is highly time-sensitive.

The cumulative impact is strongest when AI is embedded into workflow rather than used as a standalone tool. Automated alerts can shorten triage, support transfer decisions from primary stroke centers to thrombectomy-capable hospitals, and help prioritize neurointerventional teams. Industry leaders should still pair AI adoption with clinical validation, bias monitoring, cybersecurity controls, and integration into electronic health records and picture archiving systems.

Key Regional Insights Across Global Thrombectomy Markets

North America remains a high-adoption region, led by the United States and Canada, where comprehensive stroke center certification, established reimbursement, and strong neurointerventional capacity support mechanical thrombectomy utilization. Europe benefits from mature stroke networks in Germany, France, the United Kingdom, Italy, and Spain, although EU MDR compliance, health technology assessment expectations, and uneven regional access influence commercialization timelines and hospital purchasing decisions.

Asia-Pacific is an expanding opportunity base, with Japan, South Korea, Australia, China, and India investing in stroke infrastructure, imaging capacity, tertiary care networks, and specialist training. Latin America, including Brazil and Mexico, is improving thrombectomy access but remains constrained by public-private care gaps, reimbursement variability, and concentration of neurointerventional services in major urban centers. The Middle East, especially GCC countries, is expanding advanced hospital networks and stroke-ready care pathways, while Africa shows long-term need driven by stroke burden, limited CT and angiography availability, delayed presentation, and a shortage of neurointerventional specialists.

Key Group Insights for Strategic Market Prioritization

ASEAN presents a heterogeneous growth profile, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines at different stages of stroke pathway maturity, imaging access, and interventional workforce development. The GCC is characterized by government-backed hospital investment, medical tourism ambitions, and centralized purchasing, supporting adoption of advanced neurovascular technologies in leading centers. The European Union offers scale through harmonized market access principles, but MDR requirements make clinical evidence, quality systems, post-market clinical follow-up, and traceability decisive for device availability.

BRICS markets combine large stroke populations with uneven access to thrombectomy-capable centers, creating opportunities for tiered device portfolios, training, and public hospital partnerships. G7 markets remain early adopters of next-generation aspiration and stent retriever platforms because of established reimbursement, specialist density, stroke center certification, and advanced imaging infrastructure. NATO countries increasingly emphasize medical supply resilience, cybersecurity, emergency preparedness, and cross-border health system coordination, which can influence procurement expectations for critical neurovascular devices.

Key Country Insights for Blood Clot Retrieval Devices

The United States leads global commercialization through high procedure volumes, FDA-cleared technologies, mature comprehensive stroke center networks, and strong adoption of guideline-based thrombectomy workflows, while Canada benefits from coordinated provincial stroke systems and established tertiary care referral pathways. Mexico and Brazil are expanding thrombectomy access but face reimbursement, infrastructure, and regional capacity variation. In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong clinical adoption, with Germany notable for hospital and interventional capacity, France and Spain advancing organized stroke pathways, Italy balancing regional healthcare variation with specialist center development, and the United Kingdom strengthening hyperacute stroke services and transfer protocols. Russia presents demand potential but is affected by procurement complexity and uneven access to advanced neurointerventional care.

In Asia-Pacific, China and India offer substantial long-term demand because of large stroke populations, expanding tertiary care, and increasing investment in imaging and catheterization infrastructure, while Japan and South Korea are advanced markets with strong imaging availability, aging populations, and specialist adoption. Australia supports guideline-driven care across major metropolitan centers, although geography creates transfer and time-to-treatment challenges. Across all countries, the strongest opportunities align with faster diagnosis, trained interventional teams, reliable device availability, reimbursement clarity, and integrated stroke networks that connect emergency medical services, imaging, neurology, and neurointervention.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical evidence that demonstrates faster reperfusion, high rates of successful recanalization, lower complication risk, reduced embolization to new territories, and improved functional outcomes. Device portfolios should address both stent retriever and aspiration-first strategies, with attention to large vessel occlusion, distal and medium vessel navigation, clot composition variability, vessel wall safety, and compatibility with balloon guide and intermediate catheters.

Commercial execution should focus on stroke network development, physician education, simulation-based training, and partnerships with imaging and AI workflow vendors. Companies should also build region-specific access strategies, strengthen post-market surveillance, prepare for EU MDR documentation demands, and support real-world evidence generation with hospitals. The most resilient players will combine device innovation with workflow integration, supply continuity, cybersecurity readiness, and outcome-based value communication.

Research Methodology

This executive summary is based on triangulated secondary research and evidence review from authoritative sources, including WHO stroke burden references, Global Burden of Disease publications, AHA/ASA and European Stroke Organisation guidelines, peer-reviewed thrombectomy trials, regulatory databases, hospital certification frameworks, and publicly available reimbursement and procurement information.

The methodology combines clinical evidence mapping, regulatory assessment, regional healthcare infrastructure analysis, and market signal validation. Insights were screened for relevance to blood clot retrieval devices, acute ischemic stroke workflows, neurovascular intervention, AI-enabled triage, and geographic adoption patterns. Emphasis was placed on verified data, guideline-supported practice, and observable structural drivers rather than speculative market claims.

Conclusion

Blood clot retrieval devices are positioned at the intersection of clinical urgency, proven intervention, and expanding stroke system capability. Mechanical thrombectomy has moved from a specialized procedure to a core component of evidence-based care for eligible large vessel occlusion stroke, and continued adoption depends on faster diagnosis, better patient routing, consistent procedural performance, and equitable access to thrombectomy-capable centers.

The next phase of competition will be defined by integrated value: advanced device design, AI-supported workflow, strong training programs, regulatory readiness, and real-world outcomes. Organizations that align innovation with regional access needs, clinical evidence standards, and health system priorities will be best placed to support sustainable growth in the global thrombectomy market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Clot Retrieval Devices Market, by Device Type

• 7.1. Aspiration Catheter
• 7.2. Combined System
  • 7.2.1. Sequential Retrievers
  • 7.2.2. Simultaneous Retrievers
• 7.3. Stent Retriever
  • 7.3.1. Self-Expanding
  • 7.3.2. Re-sheathable

8. Blood Clot Retrieval Devices Market, by Procedure Type

• 8.1. Mechanical Thrombectomy
  • 8.1.1. Stent Retriever-Based
  • 8.1.2. Aspiration Thrombectomy
• 8.2. Pharmacomechanical Thrombectomy

9. Blood Clot Retrieval Devices Market, by Application

• 9.1. Deep Vein Thrombosis
  • 9.1.1. Distal Deep Vein Thrombosis
  • 9.1.2. Proximal Deep Vein Thrombosis
• 9.2. Ischemic Stroke
  • 9.2.1. Acute Ischemic Stroke
  • 9.2.2. Subacute And Chronic Occlusion
• 9.3. Pulmonary Embolism
  • 9.3.1. Massive Pulmonary Embolism
  • 9.3.2. Submassive Pulmonary Embolism

10. Blood Clot Retrieval Devices Market, by End User

• 10.1. Ambulatory Surgical Center
• 10.2. Hospital
  • 10.2.1. Cardiac Hospital
  • 10.2.2. Neurovascular Center
• 10.3. Specialized Vascular Clinic

11. Blood Clot Retrieval Devices Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Blood Clot Retrieval Devices Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Blood Clot Retrieval Devices Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 3D Systems, Inc.
• 15.2. Abbott Laboratories
• 15.3. AKURA MEDICAL INC.
• 15.4. AngioDynamics, Inc.
• 15.5. Bayer AG
• 15.6. Boston Scientific Corporation
• 15.7. Cardinal Health, Inc.
• 15.8. Concentric Medical, Inc
• 15.9. Inari Medical, Inc.
• 15.10. Johnson & Johnson Services, Inc.
• 15.11. Koninklijke Philips NV
• 15.12. Lonza Group AG
• 15.13. Medtronic PLC
• 15.14. MIVI Neuroscience
• 15.15. Penumbra Inc.
• 15.16. Pfizer Inc.
• 15.17. Rapid Medical
• 15.18. Shockwave Medical Inc.
• 15.19. Siemens Healthineers AG
• 15.20. Stryker Corporation
• 15.21. Surmodics, Inc.
• 15.22. Teleflex Incorporated
• 15.23. Terumo Corporation
• 15.24. Therma Bright Inc.
• 15.25. ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO. LTD.